Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

G2D2

Powering Rapid Cognitive Analysis with AI

Dr. Tom Sawyer, CFO at Cognetivity Neurosciences, discusses the benefits of AI-driven dementia detection technology for patients, health care providers, and clinical research.To find out more about Impetus: https://www.meetwithimpetus.comImpetus Digital...

Impetus Digital

- PMLiVE

Alzheimer’s Association report highlights need to improve patient-physician communication

Both individuals and primary care physicians reported a reluctance to address cognitive concerns

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration

US veterans in the early stages of the disease who meet VHA criteria will be eligible for coverage

- PMLiVE

FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Leqembi was granted accelerated approval in the US earlier this year

- PMLiVE

Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis

The commitments form part of a new UK-wide strategy to alleviate pressures on the health system

- PMLiVE

Alzheimer’s Society urges UK government to deliver on dementia plan

The strategy, announced in May last year, includes doubling dementia research funding

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

New study links hearing restorative devices to slower rate of memory decline

The use of hearing aids and cochlear implants reduced long-term cognitive decline by 19%

- PMLiVE

Lilly’s donanemab shows promise in early symptomatic Alzheimer’s comparator study

Brain amyloid clearance was achieved in 37.9% of patients treated with the investigational antibody

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links